Aktienanalyse zu Estrella Immunopharma Inc (ESLA)ESLAEstrella Immunopharma Inc

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Estrella Immunopharma Inc is not a good buy right now due to its ongoing financial struggles and significant losses. The stock is currently priced at $0.43, with a year-to-date change of -69.06% and a forward P/E ratio of 0, indicating no expected earnings growth. The main risk is its negative net income, which reached -5,544,878 USD in Q2 2025, reflecting ongoing financial instability.